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Abstract: Huntington’s disease starts slowly and progresses over a 15–20 year period. Motor changes
begin subtly, often going unnoticed by patients although they are typically visible to those close to
them. At this point, it is the early non-motor problems of HD that arguably cause the most functional
impairment. Approximately 65% of gene carriers will experience a reduction in their occupational
level, and just under half will feel unable to manage their finances independently before a clinical
diagnosis is made. Understanding what drives this impairment in activities of daily living is the key
to helping people with HD to live more independently for longer, especially in early disease. Early
cognitive decline is likely to play a contributory factor although few studies have looked directly
at this relationship. Recently, it has been shown that along with the well documented dysexecutive
syndrome seen in HD, changes in social cognition and decision-making are more common than
previously thought. Furthermore, some of the early neuropathological and neurochemical changes
seen in HD disrupt networks known to be involved in social functioning. In this review, we explore
how HD changes the way individuals interact in a social world. Specifically, we summarise the
literature on both classical and social decision-making (value-based decision-making in a social
context) along with studies of theory of mind, empathy, alexithymia, and emotion recognition in HD.
The literature specific to HD is discussed and supported by evidence from similar neurodegenerative
disorders and healthy individuals to propose future directions and potential therapeutic avenues to
be explored.
Keywords: social cognition; Huntington’s disease; decision-making
1. Introduction
Changes in social function are a prominent feature of many neurodegenerative disor-
ders, but it is becoming increasingly apparent that this is especially true in patients with
Huntington’s disease (HD). HD is an autosomal dominant neurodegenerative disease that
progresses over a 15–20 year period [1] and typically presents with a combination of cogni-
tive, motor, and neuropsychiatric problems. Motorically, choreic movements, unsteady gait,
and dysarthria are common. This is accompanied by widespread changes in cognitive func-
tion including abnormalities of psychomotor speed, working memory, emotion recognition,
and executive functions [2,3]. Finally psychiatric symptoms are common but vary widely
in their severity. Despite the motor features being the most visible signs of HD, patients
and their families often identify the non-motor symptoms as the most debilitating [4].
Until recently, the cognitive impairments in HD were thought to be exclusively a
result of damage to the frontostriatal networks and, consequently, little attention was
paid to cognitive domains other than executive function. Recently, however, there has
been increasing acknowledgement that wider neural networks are affected by the disease
process in HD, including structures within the limbic system [5,6]. The limbic system is a
functional concept that links discrete brain regions including the amygdala, hippocampus,
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hypothalamus, and thalamus due to their overlapping involvement in processes, such as
emotion response, sleep modulation, motivational behaviour, memory, and social cognition.
All of which are affected in HD.
In this review, we will focus on the emerging evidence of impairments in social
cognition and social decision-making in HD. We will discuss the literature demonstrating
that there are impairments in the way HD patients gather social information and, how
this leads to problems using that social information to make decisions in everyday life.
Finally, in the absence of any current therapeutic options, we will postulate about potential
approaches to treatments that could be explored in the future for these types of issues.
2. Social Impairment in HD
Anecdotal evidence from clinical practice highlights the diverse range of social prob-
lems that HD patients can experience. They might be insensitive, tactless, and distrusting
towards those closest to them whilst disproportionately entrusting of strangers, thereby
alienating themselves from their support networks, leaving them vulnerable to manip-
ulation. Disinhibited behaviour can leave patients (and their families) ostracised from
friendship groups and increasing social withdrawal often results in feelings of isolation and
loneliness. A lack of awareness of HD by the general public and a poor understanding of
its clinical features, can lead to patients being erroneously described as appearing “drunk”,
especially in the early stages of the condition when other more obvious features are not
present. Possibly leading to further exclusion affecting the patient’s independence.
The framework that underpins successful social living is complex, involving multiple
interdependent processes. Simplistically, it requires people to possess the ability to: (a)
detect and process social information, (b) understand their own mental states and those of
others around them (mentalize), (c) bond and form social relationships with other people,
and (d) make adaptive social decisions. Behaviour needs to be flexible and able to respond
dynamically to a range of diverse social situations but can also be influenced by socio-
economic features, cognitive capacity (attention, working memory, sensory processing),
and changes in social cognition.
Social cognition refers to the processes that underlie the way in which people interact
in a social world. In reality, it deals with the ways in which an individual gathers social
information from the environment around them and makes sense of it in their own mind. It
covers factors such as: emotion recognition, awareness (alexithymia) and reactivity, theory
of mind (ToM) and empathy (Figure 1, Table 1).
In HD, social cognitive changes have been linked to levels of self-reported social
distress [7] and are likely to underpin the observed social impairments.
To support the discussion, a comprehensive search of studies between January 1990
and January 2020 was conducted using the PUBMED database. The search terms used were:
“Huntington’s disease” (TITLE) AND “Alexithymia” (TITLE/ABSTRACT) or “theory of
mind” (TITLE/ABSTRACT), “empathy” (TITLE/ABSTRACT), “social decision-making”
(TITLE/ABSTRACT). Studies were excluded if they were review articles, case-studies,
not written in English, primarily focused on task validation or intended to establish
neural/electrophysical correlates. A preferred reporting items for systemic reviews and
meta-analyses (PRISMA) diagram providing details of the number of studies which met
the search criteria is included in Figure 2.
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 Figure 2. Search strategy: flowchart showing the number of studies included in the systemic review.
3. How HD Changes Social Cognition
3.1. Emotional Recognition
Deficits in emotional recognition have been widely reported in pre-manifest and early
HD (for review see [8]). It was initially proposed that disgust processing was preferentially
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targeted [9–14] with abnormalities found in multiple domains including disgust recognition
in vocal [13], olfactory, and gustatory modalities [15,16], as well as on facial emotion
recognition tasks [13,17,18]. However, not all studies have been able to replicate these
findings [17–24]. A recent systematic review of the literature found that a deficit in anger
recognition was the most consistently reported impairment in studies of manifest HD
patients, closely followed by impairments in disgust, then fear recognition with problems
of sadness and surprise recognition reported less frequently [8].
Calder et al. [25] looked in depth at disgust recognition in HD and found evidence to
suggest that disgust and anger were not entirely dissociable. Patients were shown a series
of different scenarios each containing one of 3 distinct disgust facial expressions: disgust
associated with an unpleasant smell (nose wrinkle), disgust associated with an unpleasant
taste (mouth gape), and disgust relating to violations of social or moral standards and
interpersonal skills (lip curl). The authors suggested that situations that evoke this later
disgust are often accompanied by feelings of anger as well as disgust, for example, we
experience both disgust and anger when we hear reports of child abuse. Calder and
colleagues showed that HD patients were significantly worse than controls at recognising
the facial expression linked with moral disgust (lip curl) but showed only a borderline
(insignificant) difference with both the other conditions.
In contrast, the literature in pre-manifest HD lacks any real consistency except to
say that deficits are typically only reported in the recognition of negative emotions [8].
Although, it is worth noting that happiness is the only positive emotion included in these
studies. Some healthy aging research has suggested that the positivity effect might be
caused by ceiling effects (that happiness is a lot easier to distinguish from the negative
emotions) [26]. Despite this, Johnson et al. [27] reported impaired recognition of anger,
disgust, fear, sadness, and surprise in a cross-sectional population of 475 pre-manifest
HD patients. Greater motor signs (although still below the threshold for diagnosis) were
associated with less accurate recognition of all negative emotions and impaired recognition
was associated with predicted time to onset. However, other studies have shown more focal
deficits preferentially affecting one or more emotion, typically disgust or anger [9,11,19,28],
or no abnormality at all [29]. Importantly, two recent studies have shown that perfor-
mance on negative emotion recognition tasks can be predictive of impending clinical
diagnosis [28,30].
Despite clear evidence that HD gene carriers have difficulty recognising emotions
from faces, even before the onset of overt disease, the implications of this are unknown.
Preliminary work has associated emotion recognition with emotional regulation in a
very small group of manifest HD patients (n = 13) [31] and, in an even smaller sub-
group of patients (n = 10) impaired emotion recognition has been shown to correlate with
impairments in the perception of trustworthiness [32]. However, further work needs to be
done to replicate and expand on these findings.
Studies in healthy individuals have shown that observing facial expressions strength-
ens decisions about whether to trust someone or not [33]. In alcoholism, difficulties with
emotion recognition have been linked to interpersonal problems [34] and in Parkinson’s
disease emotion recognition problems are associated with difficulties with social relation-
ships [35] and with social behaviour disorders [36]. No such work has been undertaken to
date in HD to our knowledge, and the extent to which problems with emotion recognition
relate to functional disability and the problems with social interactions described above,
remains unclear.
3.2. Alexithymia
Alexithymia is defined as a difficulty identifying, describing and regulating one’s
emotions [37] resulting in problems with emotional awareness, communication, and insight
(Table 1). Commonly measured using self-report questionnaires, such as the Toronto Alex-
ithymia Scale (TAS20 or TAS26) [38], alexithymia is associated with emotion recognition
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problems [39,40] in healthy individuals, and has been linked to activation of the limbic
system [41] and anterior insula [42] in functional imaging studies.
It is somewhat surprising, therefore, given the plethora of work describing emotion
recognition problems in HD, that few have looked at the role of alexithymia. Two small
studies in patients with mild HD, found that levels of alexithymia were equivalent to those
found in matched controls using an adapted version of the TAS20 [43,44] despite showing a
marked dampening of EEG activation during the voluntary production of emotional facial
expression. Conversely, in a study of a larger group of 40 patients that used the TAS26 both
manifest and premanifest gene carriers showed higher levels of alexithymia than matched
controls [45].
Evidence from other neurological conditions have found that higher levels of alex-
ithymia are associated with lower levels of empathy [46] and greater problems under-
standing others emotions or assuming their point of view [47]. In patients with TBI, it
has also been associated with a worse social and family life [48] and was found to be a
significant predictor for psychological distress [49] which the authors suggest was due to
the development of maladaptive coping strategies.
3.3. Theory of Mind
The term ToM has been used to describe an individual’s ability to understand the
presence of beliefs, feelings, intentions, and interests in other people that can differ from
their own and from reality [50] (Table 1). Multiple brain regions have been linked with
ToM, including the prefrontal cortex and superior temporal sulcus [51], although there is
some variability depending upon the tasks used.
There is increasing evidence that ToM is impaired in HD, on both first order (reflecting
on another’s thoughts and feelings) and second order (predicting another’s thoughts and
feelings) ToM tasks [52]. Patients have been shown to have difficulty with understanding
sarcasm [53,54] and ToM deficit were found on multiple different tasks including the faux
pas task, the Reading the Mind in the Eyes Task [55] and cartoon based tasks [56,57]. Recent
work has suggested that poorer ToM in HD is associated with a reduction in “altruistic
punishment” in the Dictator Game [58]. Patients are less likely than controls to punish a
third party for perceived unfair behaviour (e.g., refusing the proposed division of funds
which results in both parties leaving with no money). It is unclear whether this is because
patients have a different appreciation of what is “fair” or whether they are simply more
self-interested and, therefore, less willing to lose their share of the money.
In most cases, ToM is impaired prior to onset of clinical disease [5,59] and gets [60]
worse with disease progression [5]. A recent study suggested that the amount of infor-
mation HD gene carriers gathered when visually scanning facial stimuli [61], in part,
predicted their ability to accurately identify the thoughts, feelings, or emotions depicted
in the stimuli. Furthermore, in manifest patients, while performance does not relate to
levels of global cognitive functioning, it does appear to relate to visuospatial processing
ability [62]. Further work is needed to determine whether or not ToM deficits are secondary
to attentive problems or if patients have a fundamental problem mentalizing.
An increasing number of studies have found impaired ToM across multiple different
cohorts of HD patients. Some have tried to establish the cause of these deficits, but few
have looked to understand the consequences they bring. Although problems with ToM
are assumed to play a role in the interpersonal difficulties experienced by patients, this
has not been confirmed empirically. In the wider literature, having a better ToM has been
associated with having a more varied social network [63] while lower competency on
ToM tasks has been found to be predictive of self-reported depression and loneliness [64].
Importantly for the HD community, healthy individuals with a better ToM are also better
able to detect deception in video vignettes [65]. Being able to identify if someone is trying
to mislead you is essential in today’s world where the number of telephone, internet, and
doorstep scams are growing daily. Better understanding the relationship between ToM,
trust and deception in HD may provide important information to help safeguard patients.
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3.4. Empathy
Empathy is the ability to understand and respond appropriately to another’s thoughts,
feelings, and emotions by taking their perspective or “putting yourself in their shoes” [66].
It is an essential part of social interaction, although it has received very little attention in
the HD literature. Responding empathetically to those around you is a necessary emotional
competency that is required for building and maintaining social bonds [67].
The role of empathy in HD has been investigated by a few, small studies with mixed
results. Generally, levels of empathy in premanifest [68] and manifest HD [44,52] were
found to be similar to controls. However, where deficits have been found, they tend to
be subtle and [69] related to specific problems with cognitive empathy (the ability to see
the world from another person’s viewpoint) which are accompanied by problems with
social-skills [68] and increased levels of personal distress [59].
Far more work needs to be done before any conclusions can be drawn about the
role of empathy in the social impairment experienced in HD. Given the established links
between empathy and social interaction and the emerging evidence that lower levels of
empathy are associated with greater loneliness in older adults [70], this is an area worthy
of further investigation.
Table 1. Social cognition: processes relevant to Huntington’s disease.
Processes Assessment Scales Neural Correlates
Emotion
The subjective experience of
physiological arousal in response
to an event.
Examples include happiness,
sadness, surprise, fear, anger,
disgust and contempt
Recognition: The ability to







ability to identify and describe
emotion in oneself.







Reactivity: The ease at which
someone become emotionally
aroused and the intensity of
emotional experiences
Emotion Reactivity Scale [74]




The ability to attribute mental
states e.g., beliefs, intents, desires
and emotions, to oneself an others
Examples include: panicked,
playful, jealous, excited
Mentalising: The ability to
interpret the mental state of
oneself and other.




medial prefrontal cortex, right
superior temporal sulcus [80,81]
Empathy: The ability to feel what







medial prefrontal cortex [86]
4. How HD Changes Decision Making and Social Decision-Making
Decision-making (DM) involves the probabilistic evaluation of multiple alternatives,
ideally leading to the best option being chosen [87]. It relies on a complex interplay of
different cognitive processes to allow for the flexibility needed to adjust to a diverse range
of situations [88]. Most everyday decisions are made within a social context. Individuals
use social norms to guide their choices, they must consider the impact of their decisions on
others and commonly engage in shared decision making with other people. DM in the real
world is, therefore, heavily reliant on social cognitive functions [89]. Understanding how
DM capacity changes with disease progression in HD is crucial. Patients must make many
difficult but highly important decisions throughout the course of their disease, many of
which have implications for family and friends around them (Table 2).
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Table 2. Examples of decisions Huntington’s disease gene carriers make.
Genetic testing
Whether or not to have predictive testing
When to have predictive testing
Whether to share the results of the test with family, friends and the wider world
Reproduction
Whether or not to have children at all
Whether to have children who are also at risk of HD
Whether to use preimplantation testing or prenatal testing or natural conception
Sharing HD status
When to tell friend or new partners about gene status
Do employers need to know?
When do the DVLA need to know?
Does the GP need to know?
When to tell children that HD is in the family
Forward planning
When or if to set up an advanced directive
Is it necessary to set up a proxy decision-maker in advance?
If so, who will it be?
Care choices
Do you want to have a PEG fitted to assist feeding, if so when should it be
removed?
When is independent living no longer practical or possible?
Should care be provided at home or in a nursing care facility.
Experimental research Whether to take part in experimental studies
DM research in HD is yet to integrate the changes in social cognition detailed above
but instead has been built around a DM model defining two types of DM processes, DM
under risk and DM under ambiguity [90]. DM under risk is when all possible outcomes
(including the probability distribution of each of these outcomes) are known, allowing
for an informed evaluation and comparison of the options available. Whereas DM under
ambiguity describes the situation where the different outcomes and the probability dis-
tribution of each of these outcomes is unknown. These two concepts capture differences
in attitude towards uncertainty [90]. Gambling tasks including the Iowa Gambling task,
Cambridge Gambling task, and the Game of Dice task have all been used to investigate
this DM paradigm in HD (White, in prep).
However, contradictory results have been reported for studies comparing DM under
risk and under ambiguity. Focusing on early manifest patients, Adjeroud et al. (2017) [91]
found a reduced ability with DM under ambiguity but no differences were seen between
patients and healthy controls in their DM ability under risk. Campbell et al. (2004) [92]
came to the opposite conclusion suggesting there was an impairment in DM under risk
but no group differences in DM under ambiguity. Finally, Holl et al. (2013) [93] found no
group differences for both types of DM processes.
The remaining literature has focused exclusively on DM under risk presenting equally
mixed results. Stout et al. (2001) [94] and Galvez et al. (2017) [95] were able to find
significant group differences proposing impaired DM under risk in manifest HD patients.
In contrast, Watkins et al. (2000) [96] and Minati et al. (2011) [97] found no differences in
DM under risk between HD patients and healthy controls.
Few studies have focused on DM in pre-manifest gene expansion carriers, however
the existing research at this point suggests there are no differences from healthy controls in
DM under ambiguity or risk [91,98].
Differences in methodology and participant’s characteristics might have contributed
to these conflicting results (White, in prep). However, it could also be argued that these
basic gambling tasks are not sufficient to detect the self-reported DM deficits in HD. One of
the defining factors of naturalistic DM is its complexity regarding available information and
the cognitive skills required [88]. These highly controlled but simplistic tasks potentially
reduce the level of cognitive demands to a degree that they become manageable for people
who otherwise struggle in the real world [88]. In case of DM under risk, it is rarely the
case that all outcomes and their probability distributions are known. For example, when
deciding to speed while driving it is impossible to know how probable a crash might be,
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since many highly dynamic factors influence this possible outcome. DM under risk as
defined by research might therefore be relatively rare in everyday life.
Assessments using only DM tasks are not sufficient when characterizing the DM abili-
ties of an individual, it is also necessary to identify changes in their underlying cognitive
functions as these may be contributing to the DM impairment. In HD there are many
reported cognitive problems that are relevant to everyday DM, such as reward and pun-
ishment processing, social cognition, memory, executive functions, and motivation [1,2].
However, the gambling tasks used in HD research only challenge a small subset of those
functions (e.g., executive functions, reward and punishment processing, memory). Further,
only two DM studies included more detailed cognitive assessments using traditional neu-
ropsychological tasks [91,94]. Both found that decreased performance on some measures
of executive functions relate to maladaptive DM [91,94]. This is consistent with research
in other neurodegenerative diseases proposing a strong relationship between executive
function and basic DM [99]. Stout at al. (2001) [94] further found that HD participants
who performed better on the DM task also had better memory abilities. The proposed
explanation was that reduced memory might impair the patient’s ability to learn from
reward and punishment, leading to an inability to adjust their behaviour. It is probable
that reduced executive functions and memory underlie the reported functional DM deficit
in HD, as these represent the most fundamental cognitive functions necessary for DM
actions [99]. However, it is unlikely that they exclusively cause the clinical DM impairment,
as everyday DM does involve a much larger set of cognitive functions [100]. Many of those
functions are commonly found to be altered in HD, including social cognition [101], reward
and punishment processing [102], and metacognition [103]. Therefore, future research on
DM in HD will require a more comprehensive battery of cognitive tests, which could be
achieved by focusing on specific everyday DM scenarios and not social DM in general.
The issue of over simplistic DM task not providing valuable information on real world
DM has been recognised by the field of economics and naturalistic DM, which has led
to the development of more ecologically valid tasks [87,88]. Specifically, neuroeconomic
games have been a valuable resource to assess the impact that social context might have
on DM [87]. These paradigms mimic DM in a social environment consisting of game play
situations with multiple participants involved, creating either a competitive or collaborative
environment [104]. A large body of research focusing on psychiatric disorders associated
with social deficits has successfully employed these neuroeconomic games, recognising
their potential as diagnostic tools for such deficits [104,105]. More recently research on
vulnerability towards financial exploitation in healthy older adults and older adults with
dementia have also included these assessments, which has led some to propose that
such approaches may be more appropriate in acquiring clinically relevant information on
susceptibility to financial abuse and financial DM capacity [106–110]. Consequentially, as
HD is associated with a deficit in social cognition these neuroeconomic games might be a
more ecologically valid approach to assess DM in HD, as they include social components
creating a more realistic environment compared to traditional DM tasks. Therefore, a first
step to investigate for a functional DM deficit in HD may be to assess social DM, targeting
a DM situation likely to be affected in HD.
The above underlines the need for more research to bridge the gap between laboratory-
based DM research and real-world functioning in patients and age matched controls, as the
existing research in HD has exclusively focused on very simplistic models of DM without
considering it in the context of everyday functioning. This will help to improve the assess-
ment of DM capacity, identify vulnerable individuals, and develop more individualised
care for such people.
5. Potential Treatment Approaches
As with many aspects of HD there are currently no treatments available to help
manage the social impairment in HD. Psychoeducation can help prepare patients and
their families about the changes that may occur with the condition, as well as provide an
Brain Sci. 2021, 11, 838 9 of 15
explanation for some of their challenging behaviours as and when they arise. However,
while psychosocial interventions, such as cognitive stimulation theory, are commonplace
in other dementias [111], their efficacy has never been formally tested in HD.
Looking to the wider literature, behavioural therapies for ToM, empathy emotion
recognition and alexithymia, are beginning to be used with some degree of success although
this work is still in its infancy. To date, the only approach used directly with an HD
population has been a self-guided online training program which evoked a significant
improvement in emotion recognition accuracy in a small group (N = 22) of premanifest
and early HD participants [112].
Anecdotally, alexithymia may be responsive to cognitive behavioural therapy (CBT),
group therapy [113] or psychotherapy although the empirical evidence supporting this
is sparce. Focused training strategies using neurocognitive training [114] and imitation
therapy [115] have be found to improve ToM in patients with schizophrenia. Similarly,
motivational-based interventions have been shown to boost empathy in healthy college
students with real-life implications including an increase in their number of friends [116].
These methodologies appear to be accessible for an early or premanifest HD population,
which is also the group who would benefit most, therefore these strategies may be a future
therapeutic avenue worth exploring.
Going forward, a better understanding of the underlying neural basis for these deficits
in social cognition in HD would be helpful. Some brain structures (e.g., amygdala) and
neurotransmitters (e.g., oxytocin) have been heavily linked to the processing of social
information and are thus obvious treatment targets.
In this respect, there is a 45% reduction in the number of oxytocin-expressing neurones
and a 24% reduction in the vasopressin-expressing neurones in the HD hypothalamus [117]
compared to controls even at very early stages of the disease [118]. Evidence from animal
models suggests that an imbalance in the oxytocin-vasopressin networks may be linked to
the psychiatric phenotype in HD [119]. In humans, oxytocin levels have been shown to
correlate with performance on social cognition tasks in a very small (n = 12) population
of early manifest HD patients [120]. Furthermore, intranasal administration normalised
brain activity in response to disgust stimuli in 9 HD patients [121]. In healthy individuals,
higher levels of oxytocin in the body have been shown to reduce anxiety and stress in
social situations [122,123]. When manipulated artificially, oxytocin can increase trust [124],
improve mentalizing performance on ToM tasks [125] and enhance amygdala dependent
social learning and emotional empathy in healthy controls [126].
Taken together, there is sufficient justification to support further investigation of this
pathway as a potential treatment for social impairment in HD.
6. Conclusions
Being able to function in a social world is an essential part of everyday life. Human
beings are interdependent, social creatures who strive for a sense of “belonging” within a
wider social group [127]. A sense of isolation or a perception of being disconnected from
the environment around us leads to feelings of loneliness [128] which, in turn, has been
linked to depression, anxiety, low life satisfaction, and suicidal ideation [129,130]. Social
isolation has been shown to be a significant risk factor for dementia in later life [131] and
conversely, larger and more complex social networks have been found to be associated
with better cognitive function in patients with Alzheimer’s disease, independent of their
pathology [132].
In other conditions, such as schizophrenia, problems with social cognition have been
linked to poorer social outcomes and social functioning [133–135]. Social dysfunction and
social isolation have a reciprocal relationship, whereby social dysfunction can lead to social
isolation which, in turn, exacerbates the problem creating a positive feedback situation.
Research investigating social cognition in HD is still in its infancy. To date the work has
lacked focus. Multiple studies have used small cohorts of heterogeneous patients to look
at isolated aspects of social cognition and related performance back to stages of disease
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progression in a descriptive fashion. Little attention has been given to understanding
how changes in social cognition relate to one another or to the functional impairment
experienced by patients. Furthermore, symptomatic treatments are desperately needed for
HD and, arguably, more attention should be directed on processes, such as social cognition
given their relationship with quality of life and the impact on the patient’s ability to live
independently. The foundations have been set but there is still a significant amount of
work to do in this area over the next few years.
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